Neurofibroma, Plexiform - 25 Studies Found
Completed |
: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas :
: 2006-06-19 :
|
Completed |
: Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas :
: 2004-01-13 : Drug: Pirfenidone Pirfenidone orally as capsules three times a day approximately every 8 hours for cycle |
Active, not recruiting |
: Study of PEG-Intron for Plexiform Neurofibromas : Plexiform Neurofibroma : 2006-11-02 : Drug: PEG-Intron |
Recruiting |
: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas : Plexiform Neurofibromas : 2014-06-25 : Drug: Imatinib Mesylate oral administration Other Na |
Terminated |
: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) : Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 : 2011-05-27 : Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Completed |
: Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas :
: 2008-07-31 :
|
Recruiting |
: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery :
: 2015-04-02 :
|
Recruiting |
: Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) :
: 2015-09-05 |
Suspended |
: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas :
|
Recruiting |
: Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain :
: 2015-06-12 : Other: Acceptance and Commitment Therapy (ACT) Acceptance and Commitment Therapy (ACT), a newer generati |